Clinical trial / 2022
One year after stopping semaglutide and lifestyle intervention, participants regained two-thirds of their prior weight loss.
In the STEP 1 trial extension, 327 participants who completed 68 weeks of once-weekly semaglutide 2.4 mg or placebo plus lifestyle intervention were followed for 52 weeks after discontinuing all treatments. Mean weight loss from week 0 to 68 was 17.3% (SD: 9.3%) with semaglutide and 2.0% (SD: 6.1%) with placebo. Following withdrawal, semaglutide participants regained 11.6 percentage points (SD: 7.7) of lost weight by week 120, yielding a net weight loss of 5.6% (SD: 8.9%) from week 0 to 120, while placebo participants regained 1.9 percentage points (SD: 4.8; net loss 0.1%). Cardiometabolic improvements seen at week 68 with semaglutide reverted toward baseline at week 120 for most variables.
- Study type
- Randomized controlled trial extension
- Who was studied
- 327 adults without diabetes with BMI >= 30 kg/m2 (or >= 27 with >= 1 co-morbidity)
- What was measured
- Changes in body weight and cardiometabolic risk factors after treatment withdrawal
THE PAPER
Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.
Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, Lingvay I, McGowan BM, Oral TK, Rosenstock J, Wadden TA, Wharton S, Yokote K, Kushner RF, STEP 1 Study Group. Diabetes Obes Metab, 2022.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.